Literature DB >> 14613938

Nucleoside and RNA triphosphatase activities of orthoreovirus transcriptase cofactor mu2.

Jonghwa Kim1, John S L Parker, Kenneth E Murray, Max L Nibert.   

Abstract

The mammalian Orthoreovirus (mORV) core particle is an icosahedral multienzyme complex for viral mRNA synthesis and provides a delimited system for mechanistic studies of that process. Previous genetic results have identified the mORV mu2 protein as a determinant of viral strain differences in the transcriptase and nucleoside triphosphatase activities of cores. New results in this report provided biochemical and genetic evidence that purified mu2 is itself a divalent cation-dependent nucleoside triphosphatase that can remove the 5' gamma-phosphate from RNA as well. Alanine substitutions in a putative nucleotide binding region of mu2 abrogated both functions but did not affect the purification profile of the protein or its known associations with microtubules and mORV microNS protein in vivo. In vitro microtubule binding by purified mu2 was also demonstrated and not affected by the mutations. Purified mu2 was further demonstrated to interact in vitro with the mORV RNA-dependent RNA polymerase, lambda3, and the presence of lambda3 mildly stimulated the triphosphatase activities of mu2. These findings confirm that mu2 is an enzymatic component of the mORV core and may contribute several possible functions to viral mRNA synthesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14613938     DOI: 10.1074/jbc.M308637200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Conserved sequence motifs for nucleoside triphosphate binding unique to turreted reoviridae members and coltiviruses.

Authors:  Max L Nibert; Jonghwa Kim
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  A post-entry step in the mammalian orthoreovirus replication cycle is a determinant of cell tropism.

Authors:  Laura S Ooms; Takeshi Kobayashi; Terence S Dermody; James D Chappell
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

3.  Structure of avian orthoreovirus virion by electron cryomicroscopy and image reconstruction.

Authors:  Xing Zhang; Jinghua Tang; Stephen B Walker; David O'Hara; Max L Nibert; Roy Duncan; Timothy S Baker
Journal:  Virology       Date:  2005-09-08       Impact factor: 3.616

4.  Gene-specific inhibition of reovirus replication by RNA interference.

Authors:  Takeshi Kobayashi; James D Chappell; Pranav Danthi; Terence S Dermody
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

5.  ATP hydrolysis and AMP kinase activities of nonstructural protein 2C of human parechovirus 1.

Authors:  Olga Samuilova; Camilla Krogerus; Igor Fabrichniy; Timo Hyypiä
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis.

Authors:  Maya Shmulevitz; Shashi A Gujar; Dae-Gyun Ahn; Adil Mohamed; Patrick W K Lee
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

7.  Silencing and complementation of reovirus core protein mu2: functional correlations with mu2-microtubule association and differences between virus- and plasmid-derived mu2.

Authors:  John Carvalho; Michelle M Arnold; Max L Nibert
Journal:  Virology       Date:  2007-04-23       Impact factor: 3.616

8.  Conformational changes accompany activation of reovirus RNA-dependent RNA transcription.

Authors:  Israel I Mendez; Scott G Weiner; Yi-Min She; Mark Yeager; Kevin M Coombs
Journal:  J Struct Biol       Date:  2008-01-26       Impact factor: 2.867

9.  Identification of functional domains in reovirus replication proteins muNS and mu2.

Authors:  Takeshi Kobayashi; Laura S Ooms; James D Chappell; Terence S Dermody
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

10.  Probing the transcription mechanisms of reovirus cores with molecules that alter RNA duplex stability.

Authors:  Alexander A Demidenko; Max L Nibert
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.